NCT04397276CompletedPhase 1
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- First submitted
- 18 May 2020
- Start date
- 10 Jul 2020
- Primary completion date
- 16 Sept 2025
- Lead sponsor
- Janssen Research & Development, LLC
- Diseases
- Prostate cancer
- NCT number
- NCT04397276
- EU CT number
- 2024-516351-40-00
- EudraCT number
- 2019-004885-16
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 82
- From 10 Jul 2020 to the primary completion date, 16 Sept 2025
- 5 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of any other anticancer treatment or investigational agent for the treatment of advanced disease
- Toxicities related to prior anticancer treatments have not returned to Grade less than or equal to (\<=) 1 or baseline, except for alopecia and vitiligo
- Solid organ or bone marrow transplantation
Other illness
- Known allergies, hypersensitivity, or intolerance to JNJ-70218902 or its excipients
Other
- Known brain metastases
- Certain comorbidities
Who the study is looking for
- Histology: Metastatic castration-resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma. Adenocarcinoma with small-cell or neuroendocrine features is allowed
- Measurable or evaluable disease
- Prior treatment with at least 1 prior novel androgen receptor (AR)-targeted therapy or chemotherapy
- If the participant is receiving treatment with gonadotropin-releasing hormone agonists or antagonist analogs (GnRH), this therapy must have been initiated prior to first dose of study drug and must be continued throughout the study
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- Adequate organs functions
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
| BC Cancer Agency - Vancouver BC Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Rambam Medical Center Coordinator of this site? Confirm its status | Haifa | Israel | Unknown status |
| Sourasky Medical Center Coordinator of this site? Confirm its status | Tel Aviv | Israel | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.